Yes.
One vaccine for the prevention of H5N1 influenza, commonly referred to as avian influenza or “bird flu,” contains the adjuvant AS03, an oil-in-water emulsion. The AS03 adjuvant is made up of the oily compounds, D,L-alpha-tocopherol (vitamin E) and squalene, and an emulsifier, polysorbate 80, which helps ingredients mix together and keep them from separating, and water containing small amounts of salts. The vaccine is not commercially available, but included within the U.S. government’s Strategic National Stockpile if public health officials determine it is needed.
Fluad, a vaccine for the prevention of seasonal influenza in individuals 65 years of age and older, contains MF59, also an oil-in-water emulsion of squalene oil.
Heplisav-B, a vaccine for the prevention of infection caused hepatitis B virus in individuals 18 years of age and older, contains CpG 1018. Cyfendus, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis (Anthrax) in individuals 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs, contains CpG 7909. Both CpG 1018 and CpG 7909 are adjuvants based on synthetic DNA sequences. Cyfendus is included in the Strategic National Stockpile to be used for post-exposure prophylaxis with antibiotics in the event of a terrorist attack with anthrax.
Shingrix, a vaccine for the prevention of shingles in individuals 50 years of age and older, contains AS01B. Arexvy, a vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, contains AS01E. Both AS01B and AS01E are made of up MPL, a purified fat-like substance, and QS-21 which is purified from the bark of the Quillaja saponaria (soap bark) evergreen tree native to central Chile.
